River Vision Development Corporation Report issue

For profit Phase 2
Founded: New York NY United States (2011)
Status: Acquired by Horizon Pharma (2017) → now Amgen

Organization Overview

First Clinical Trial
2013
NCT01868997
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

teprotumumab (Tepezza) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 1)

Eye Diseases (Phase 2)

Graves Ophthalmopathy (Phase 2)

Macular Edema (Phase 1)

Thyroid Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1